Takeda announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1 and intends to rapidly initiate the first global Phase 3 trials of TAK-861 in first half of fiscal year 2024.
Search 
+86 21 5895 0110 
![5-[(3-chloro-2-fluorophenyl)methyl]-3,3-difluoro-4-hydroxypyrrolidin-2-one](https://images.chemenu.com/attachments/products_new/svg/2460728-19-0.svg)
